Neurodegenerative diseases, such as Parkinson’s disease, are a major public health issue given the aging population in Europe and beyond. While curative pharmacological treatment of these diseases is not in sight, cell replacement therapies (CTs) are considered very promising, in particular with the advent of stem-cell reprogramming technologies. However, a fundamental challenge in the medical app ...